MX2020000816A - Tratamiento de lesiones no inflamatorias. - Google Patents

Tratamiento de lesiones no inflamatorias.

Info

Publication number
MX2020000816A
MX2020000816A MX2020000816A MX2020000816A MX2020000816A MX 2020000816 A MX2020000816 A MX 2020000816A MX 2020000816 A MX2020000816 A MX 2020000816A MX 2020000816 A MX2020000816 A MX 2020000816A MX 2020000816 A MX2020000816 A MX 2020000816A
Authority
MX
Mexico
Prior art keywords
methyl
inflammatory lesions
mono
naphthacene
tetrahydroxy
Prior art date
Application number
MX2020000816A
Other languages
English (en)
Inventor
Alexandre Kaoukhov
David Berk
Vilma Sniukiene
Carsten Schmitz
Original Assignee
Almirall Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Llc filed Critical Almirall Llc
Publication of MX2020000816A publication Critical patent/MX2020000816A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

En el presente documento se proporcionan procedimientos de tratamiento de lesiones no inflamatorias y síntomas de las mismas que comprenden la administración a un paciente que lo necesita de una cantidad terapéuticamente eficaz de amida de ácido (4S,4aS,5aR,12aS)-4-dimetilamino-3,10,12,12a-tetrahidroxi-7-[(met oxi(metil)amino)-metil]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahidro -naftaceno-2-carboxílico o sales farmacéuticamente aceptables de la misma. En ciertas realizaciones se administra una sal mono clorhidrato cristalina, mono mesilato o mono sulfato de amida de ácido (4S,4aS,5aR,12aS)-4-dimetilamino-3,10,12,12a-tetrahidroxi-7- [(metoxi(metil)amino)-metil]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octa hidro-naftaceno-2-carboxílico.
MX2020000816A 2017-07-21 2018-07-20 Tratamiento de lesiones no inflamatorias. MX2020000816A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762535572P 2017-07-21 2017-07-21
PCT/IB2018/000938 WO2019016609A1 (en) 2017-07-21 2018-07-20 TREATMENT OF NON-INFLAMMATORY LESIONS

Publications (1)

Publication Number Publication Date
MX2020000816A true MX2020000816A (es) 2020-08-17

Family

ID=63713912

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000816A MX2020000816A (es) 2017-07-21 2018-07-20 Tratamiento de lesiones no inflamatorias.

Country Status (12)

Country Link
US (1) US20200222432A1 (es)
EP (1) EP3654988B1 (es)
JP (1) JP2020527607A (es)
CN (1) CN111343991A (es)
AU (1) AU2018303807B2 (es)
BR (1) BR112020000968A2 (es)
CA (1) CA3070663A1 (es)
ES (1) ES2962380T3 (es)
IL (1) IL272124A (es)
MA (1) MA49641A (es)
MX (1) MX2020000816A (es)
WO (1) WO2019016609A1 (es)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
NL6607516A (es) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
WO2002080932A1 (en) * 2001-04-05 2002-10-17 Collagenex Pharmaceuticals, Inc. Methods of treating acne
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
ES2701725T3 (es) 2006-12-21 2019-02-25 Paratek Pharm Innc Compuestos de tetraciclina sustituida para el tratamiento de trastornos inflamatorios de la piel
JP5583411B2 (ja) 2006-12-21 2014-09-03 パラテック ファーマシューティカルズ インコーポレイテッド 細菌感染、ウイルス感染、および寄生虫感染の治療のためのテトラサイクリン誘導体
CA2724412A1 (en) * 2008-05-21 2009-11-26 Galderma Research & Development Maintenance therapy regimen for treating acne
CN102056481A (zh) * 2008-06-05 2011-05-11 陶氏制药科学公司 包含低浓度的在水和水混溶性有机溶剂中的悬浮液形式的过氧苯甲酰的局部药物制剂
CA2769640A1 (en) * 2009-07-30 2011-02-03 Allergan, Inc. Combination of dapsone with adapalene
US20140121188A1 (en) * 2009-10-02 2014-05-01 Foamix Ltd. Compositions for the improved treatment of acne and related disorders
LT2707003T (lt) * 2011-05-12 2019-10-10 Paratek Pharmaceuticals, Inc. Kristalinės (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksirūgšties amido druskos ir jų panaudojimo būdai
IL225239A0 (en) * 2012-03-15 2013-06-27 Meir Eini Compounds for the treatment of acne and related diseases
GB201615693D0 (en) * 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations

Also Published As

Publication number Publication date
WO2019016609A1 (en) 2019-01-24
KR20200031126A (ko) 2020-03-23
ES2962380T3 (es) 2024-03-18
US20200222432A1 (en) 2020-07-16
AU2018303807B2 (en) 2023-08-24
JP2020527607A (ja) 2020-09-10
IL272124A (en) 2020-03-31
EP3654988A1 (en) 2020-05-27
CA3070663A1 (en) 2019-01-24
BR112020000968A2 (pt) 2020-07-14
AU2018303807A1 (en) 2020-02-13
MA49641A (fr) 2021-06-02
CN111343991A (zh) 2020-06-26
EP3654988B1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
TR201911086T4 (tr) (4s,4as,5ar,12as)-4- Dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftasen-2-karboksilik asit amidin kristalli tuzları ve bunların kullanım yöntemleri.
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
CA2588296A1 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
JP2014526503A5 (es)
RU2014111069A (ru) Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
NZ714963A (en) Compositions and methods for treating anemia
AU2014340303A1 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
MX336187B (es) Metodo para tratar el mal de parkinson.
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
RU2013108258A (ru) Применение разагилина для лечения обонятельной дисфункции
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
IL273169B1 (en) A new combination of active substances for the treatment of advanced lymphoid interstitial lung diseases
HK1176318A1 (en) Injection device
CA2632207C (en) Use of calcitonin for the treatment of ra
RU2018110580A (ru) Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
NZ751972A (en) Treatment of prurigo nodularis
MX2020000816A (es) Tratamiento de lesiones no inflamatorias.
JP2020533402A5 (es)
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
AR115994A1 (es) Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático
MX2022003845A (es) Tratamientos cognitivos medicinales.
FI3864053T3 (fi) Rms:n hoito vaihtohoidolla